Market Closed -
London S.E.
11:35:06 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
2
GBX
|
-6.98%
|
|
-36.51%
|
-61.17%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
25.78
|
11.7
|
9.943
|
168.7
|
9.013
|
11.75
|
Enterprise Value (EV)
1 |
25.17
|
10.19
|
10.18
|
168.5
|
8.93
|
12.7
|
P/E ratio
|
-5.34
x
|
-1.76
x
|
-1.18
x
|
-33.3
x
|
-1.57
x
|
-2.55
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.89
x
|
11.5
x
|
107
x
|
526
x
|
14.4
x
|
142
x
|
EV / Revenue
|
8.68
x
|
10
x
|
110
x
|
525
x
|
14.3
x
|
153
x
|
EV / EBITDA
|
-8.43
x
|
-2.44
x
|
-6.7
x
|
-47
x
|
-1.61
x
|
-3.22
x
|
EV / FCF
|
-3.96
x
|
39.9
x
|
-3.05
x
|
85.3
x
|
-3.64
x
|
-5.21
x
|
FCF Yield
|
-25.2%
|
2.5%
|
-32.8%
|
1.17%
|
-27.5%
|
-19.2%
|
Price to Book
|
2.75
x
|
1.85
x
|
4.71
x
|
-753
x
|
5.85
x
|
13.4
x
|
Nbr of stocks (in thousands)
|
116,498
|
136,483
|
172,920
|
202,070
|
212,070
|
261,115
|
Reference price
2 |
0.2212
|
0.0858
|
0.0575
|
0.8350
|
0.0425
|
0.0450
|
Announcement Date
|
8/30/18
|
7/25/19
|
9/30/20
|
9/28/21
|
9/30/22
|
7/28/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2.901
|
1.016
|
0.0926
|
0.3209
|
0.6242
|
0.0828
|
EBITDA
1 |
-2.985
|
-4.171
|
-1.519
|
-3.582
|
-5.558
|
-3.949
|
EBIT
1 |
-3.977
|
-4.495
|
-1.849
|
-3.602
|
-5.574
|
-3.964
|
Operating Margin
|
-137.11%
|
-442.25%
|
-1,996.67%
|
-1,122.65%
|
-893.05%
|
-4,784.67%
|
Earnings before Tax (EBT)
1 |
-3.976
|
-5.771
|
-1.847
|
-4.801
|
-5.572
|
-4.263
|
Net income
1 |
-3.976
|
-5.771
|
-7.079
|
-4.85
|
-5.712
|
-4.288
|
Net margin
|
-137.07%
|
-567.76%
|
-7,643.69%
|
-1,511.59%
|
-915.03%
|
-5,176.11%
|
EPS
2 |
-0.0415
|
-0.0488
|
-0.0487
|
-0.0251
|
-0.0271
|
-0.0176
|
Free Cash Flow
1 |
-6.354
|
0.2554
|
-3.341
|
1.976
|
-2.452
|
-2.437
|
FCF margin
|
-219.06%
|
25.13%
|
-3,607.75%
|
615.81%
|
-392.78%
|
-2,941.61%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/30/18
|
7/25/19
|
9/30/20
|
9/28/21
|
9/30/22
|
7/28/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
0.24
|
-
|
-
|
0.95
|
Net Cash position
1 |
0.6
|
1.51
|
-
|
0.25
|
0.08
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.1567
x
|
-
|
-
|
-0.2417
x
|
Free Cash Flow
1 |
-6.35
|
0.26
|
-3.34
|
1.98
|
-2.45
|
-2.44
|
ROE (net income / shareholders' equity)
|
-48.6%
|
-73.6%
|
-43.8%
|
-509%
|
-847%
|
-353%
|
ROA (Net income/ Total Assets)
|
-25.6%
|
-28.5%
|
-21.1%
|
-88.3%
|
-139%
|
-52.7%
|
Assets
1 |
15.53
|
20.25
|
33.6
|
5.495
|
4.118
|
8.137
|
Book Value Per Share
2 |
0.0800
|
0.0500
|
0.0100
|
-0
|
0.0100
|
0
|
Cash Flow per Share
2 |
0.0100
|
0.0100
|
0
|
0
|
0
|
0.0100
|
Capex
1 |
0.08
|
0.02
|
0.16
|
0
|
0.03
|
-
|
Capex / Sales
|
2.67%
|
1.86%
|
175.61%
|
0.42%
|
4.4%
|
-
|
Announcement Date
|
8/30/18
|
7/25/19
|
9/30/20
|
9/28/21
|
9/30/22
|
7/28/23
|
|
1st Jan change
|
Capi.
|
---|
| -61.17% | 12.61M | | +31.96% | 272M | | +33.74% | 261M | | +49.42% | 194M | | +44.98% | 131M | | -28.57% | 121M | | +115.91% | 119M | | 0.00% | 86.82M | | +150.00% | 75.33M | | +1.20% | 55.24M |
Medical Farming
|